Overview
Kevin Norrett serves as Chief Business Officer at Ovid Therapeutics [1][3]. Norrett brings over 25 years of experience in product development, portfolio optimization, and strategic oversight in life sciences and commercial strategy [2]. Previously, Norrett held the position of Chief Business Officer at Soleno Therapeutics [4], where Norrett contributed to corporate strategy and portfolio expansion prior to the company's $2.9 billion acquisition by Neurocrine Biosciences [2]. Norrett's career also includes roles as Chief Operating Officer at Codexis [5], Chief Business and Commercial Officer at Sierra Oncology [6], Chief Commercial Officer at Angion [7], and multiple positions at Aimmune Therapeutics [8][9][10]. Norrett holds an MBA in Health Care Management from UC Berkeley's Haas School of Business [11], an M.S. in Biochemistry and Molecular Biology from UCLA [12], and a B.S. in Biological Sciences from UC Davis [13].
Profile introduction
With over 25 years of experience, I currently serve as the Chief Business Officer at Ovid Therapeutics, leveraging expertise in product development, portfolio optimization, and strategic oversight. My focus lies in delivering transformative outcomes at the intersection of life sciences and commercial strategy, supported by a proven track record of leadership in C-suite roles. In my previous role at Soleno Therapeutics, I played a pivotal part in shaping corporate strategy and driving portfolio expansion, culminating in the $2.9 billion acquisition by Neurocrine Biosciences. My work has cons…
Career history
- Chief Business OfficerJul 2026 to presentOvid Therapeutics
- Chief Business OfficerNov 2025 to Jul 2026Soleno Therapeutics, Inc.
- Chief Operating OfficerOct 2022 to Nov 2025Codexis, Inc.
- Chief Business and Commercial OfficerAug 2020 to Oct 2022Sierra Oncology
- Chief Commercial Officer (CCO)Jul 2019 to Aug 2020Angion
- VP, Marketing, Market Access & Commercial OperationsMay 2019 to Jul 2019Aimmune Therapeutics
- VP, Global Market Access & US Commercial OperationsDec 2018 to May 2019Aimmune Therapeutics
- VP, Global Market Access & Customer SolutionsJan 2017 to Dec 2018Aimmune Therapeutics
Education
MBA, Health Care Management Certificate2003 - 2005University of California, BerkeleyHaas School of Business
M.S., Biochemistry and Molecular Biology1997 - 1999UCLA
- B.S., Biological SciencesSep 1991 - Sep 1995University of CaliforniaDavis
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.